Literature DB >> 28081946

[Hepatocellular carcinoma surveillance].

Charlotte Costentin1.   

Abstract

Hepatocellular carcinoma related mortality is one of the highest among all cancers. Ninety percent of all hepatocellular carcinoma develop in the context of liver cirrhosis. Liver cirrhosis is not recognized prior to the diagnosis of hepatocellular carcinoma in 25 % of the cases, despite the existence of risk factors. Hepatocellular carcinoma is diagnosed within a surveillance program in less than 25 % of the cases. Ultrasound screening for hepatocellular carcinoma every 6 months increases chances to diagnose HCC at an early stage amenable to curative treatment, and increases survival. Interval greater than 7months between ultrasound imaging has a significant negative impact on survival. All patients diagnosed with cirrhosis have to perform an ultrasound screening for hepatocellular carcinoma and comply with the six months rule.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28081946     DOI: 10.1016/j.lpm.2016.11.006

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  14 in total

1.  [Matrine suppresses stemness of hepatocellular carcinoma cells by regulating β-catenin signaling pathway].

Authors:  Meiqin Dai; Zhuo Cai; Nana Chen; Jinzhou Li; Jiayong Wen; Lizhuan Tan; Dan Guo
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-10-30

2.  Stereotactic body radiation therapy versus radiofrequency ablation in patients with small hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Jiawei Hong; Linping Cao; Haiyang Xie; Yuanxing Liu; Jun Yu; Shusen Zheng
Journal:  Hepatobiliary Surg Nutr       Date:  2021-10       Impact factor: 8.265

3.  Weighted gene co-expression network analysis reveals prognostic and diagnostic significance of PAQR4 in patients with early and late hepatocellular carcinoma.

Authors:  Tianhang Feng; Chunyou Lai; Deyuan Zhong; Le Luo; Haibo Zou; Guan Wang; Qinyan Yang; Yutong Yao; Xiaolun Huang
Journal:  J Gastrointest Oncol       Date:  2022-04

Review 4.  How Dysregulated Ion Channels and Transporters Take a Hand in Esophageal, Liver, and Colorectal Cancer.

Authors:  Christian Stock
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

5.  Relationship between plasma cell-free DNA (cfDNA) and prognosis of TACE for primary hepatocellular carcinoma.

Authors:  Kun Ma; Jiayun Liu; Youjin Wang; Yubin Zhong; Zhenfeng Wu; Ruiying Fan; Shanfeng Guo
Journal:  J Gastrointest Oncol       Date:  2020-12

6.  Inhibitory effects of genistein in combination with gefitinib on the hepatocellular carcinoma Hep3B cell line.

Authors:  Yongxi Tong; Mingshan Wang; Haijun Huang; Jiajie Zhang; Yicheng Huang; Yingjun Chen; Hongying Pan
Journal:  Exp Ther Med       Date:  2019-09-19       Impact factor: 2.447

7.  Sublethal hyperthermia enhances anticancer activity of doxorubicin in chronically hypoxic HepG2 cells through ROS-dependent mechanism.

Authors:  Qi Wang; Hui Zhang; Qian-Qian Ren; Tian-He Ye; Yi-Ming Liu; Chuan-Sheng Zheng; Guo-Feng Zhou; Xiang-Wen Xia
Journal:  Biosci Rep       Date:  2021-06-25       Impact factor: 3.840

Review 8.  Diagnostic and prognostic value of circular RNAs in hepatocellular carcinoma.

Authors:  Jin-Yu Sun; Xiao-Yu Zhang; Yi-Zhi Cao; Xiao Zhou; Jian Gu; Xiao-Xin Mu
Journal:  J Cell Mol Med       Date:  2020-04-13       Impact factor: 5.310

9.  Screening and Identification of Potential Biomarkers for Hepatocellular Carcinoma: An Analysis of TCGA Database and Clinical Validation.

Authors:  Xianli Wei; Junzi Ke; Haonan Huang; Shikun Zhou; Ao Guo; Kun Wang; Yujuan Zhan; Cong Mai; Weizhen Ao; Fuda Xie; Rongping Luo; Jianyong Xiao; Hang Wei; Bonan Chen
Journal:  Cancer Manag Res       Date:  2020-03-17       Impact factor: 3.989

10.  Mitofusin-2 (Mfn-2) Might Have Anti-Cancer Effect through Interaction with Transcriptional Factor SP1 and Consequent Regulation on Phosphatidylinositol Transfer Protein 3 (PITPNM3) Expression.

Authors:  Tao Tang; Xuxiong Tao; Xing Bao; Jun Chen; Jingyu Dai; Jinjun Ye; Yukuang Yan
Journal:  Med Sci Monit       Date:  2020-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.